COMMUNITY CLINICAL ONCOLOGY PROGRAM

马约诊所通过车辆的北中央癌症治疗 集团（NCCTG）将作为主要的研究基地， CCOP：Alton Ochsner医学基金会，Carle癌症中心，雪松 急流肿瘤项目，杜卢斯诊所，盖辛格诊所和医疗 中心，伊利诺伊州肿瘤学研究协会，爱荷华州肿瘤学研究， 协会拉皮德城区域肿瘤组，圣卢克医院， 苏族社区癌症联盟和托莱多。 我们还将作为 非CCOP癌症控制协议活动研究基地 参与者和我们小组之外的多个CCOP， 为团体间癌症治疗和癌症控制协议做出贡献 我们领导的。 我们将与我们的附属CCOP合作规划 他们的计划，并进行适当的继续教育， 工作坊. 我们将为他们的数据提供培训和积极支持 管理人员和肿瘤科护士。 我们将协调他们的多学科 参与临床癌症研究方案。 这将包括 制定和维护手术的标准报告程序， 病理学和放射治疗。 我们将定期举行会议， CCOP的审查正在进行的研究，规划未来的研究， 相关专业活动。 我们将继续严格的质量 过去证明非常成功的控制程序，以及 按照指示升级这些程序。 我们将不断监测CCOP 不仅通过及时审查患者数据表、病理学 材料、手术报告和放射治疗端口片，而且 通过定期随机安排的监测站点访问。 我们将与 每个CCOP参与者，以帮助他们成熟为临床 investigators. 我们将协助他们制定新的协议， 他们将分享领导权，我们将与他们合作， 出版物以及在国家和区域会议上的发言。 我们将尽一切努力使他们对自己的工作感到自豪。 参与国家癌症计划。 优先考虑这个 赠款期间将扩大我们的控制工作到癌症 结合相关的基本实验室支持进行预防。

The Mayo Clinic through the vehicle of the North Central Cancer Treatment Group (NCCTG) will serve as primary research base for the following CCOP's: Alton Ochsner Medical Foundation, Carle Cancer Center, Cedar Rapids Oncology Project, the Duluth Clinic, Geisinger Clinic nd Medical Center, Illinois Oncology Research Association, Iowa Oncology Research, Association Rapid City Regional Oncology Group, St. Luke's Hospitals, Sioux Community Cancer Consortium, and Toledo. We will also serve as research base for cancer control protocol activity of non-CCOP participants and for the multiple CCOP's outside of our group who contribute to intergroup cancer treatment and cancer control protocols which we lead. We will cooperate with our affiliated CCOP's in planning their program and in conducting appropriate continuing education and workshops. We will provide training and active support for their data managers and oncology nurses. We will coordinate their multidisciplinary involvement in clinical cancer research protocols. This will include evolving and maintaining standard reporting procedures for surgery, pathology, and radiation therapy. We will hold regular meetings of the CCOP's for review of ongoing research, planning future research, and for related professional activities. We will continue the rigid quality control procedures which have proved so successful in the past, and upgrade these procedures as indicated. We will constantly monitor CCOP performance not only by timely review of patient data sheets, pathology material, operative reports, and radiation therapy port films, but also by periodic randomly scheduled monitoring site visits. We will work with each CCOP participant to aid in their maturation as clinical investigators. We will assist them in developing new protocols for which they will share leadership and we will work with them in preparing publications as well as presentations for national and regional meetings. We will make every effort to provide them with justifiable pride in their participation in the National Cancer Program. A high priority over this grant period will be expansion of our control efforts into cancer prevention with incorporation of associated basic laboratory support.